Clinical Phenotype Transition in Pemphigus May Suggest Undertreatment with Rituximab: Findings from a Retrospective Single-Centre Analysis of Relapsed Patients
Clinical phenotype transition was observed exclusively in mcPV patients, suggesting that such changes do not represent a true alteration in disease subtype but rather reflect persistent activity of the same pathogenic autoantibody due to suboptimal B-cell depletion, suggesting undertreatment with rituximab. These findings support the need to refine rituximab treatment regimens to achieve complete B-cell depletion, reduce relapse rates, and optimize long-term disease control in pemphigus.
Authors
- Joost M. Meijer (ORCID: https://orcid.org/0000-0001-7654-3528)
- Gilles F.H. Diercks (ORCID: https://orcid.org/0000-0001-8053-216X)
- Anne-Lise Strandmoe (ORCID: https://orcid.org/0009-0000-0648-5043)
- Marjolein A J Hiel (ORCID: https://orcid.org/0000-0002-7715-1697)
- Laura van Nijen-Vos (ORCID: https://orcid.org/0009-0003-9344-1111)
- Gonnie H.J. Meijer
- Peter Heeringa
- Jeroen Bremer
- L. Joost van Pelt
- Barbara Horváth
- A. Miranda Nijenhuis
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
Publication Details
- Journal
- Dermatology
- Published
- 2026-01-19
- DOI
- https://doi.org/10.1159/000550300
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00